AACR: MD Anderson researchers share cancer breakthroughs
ABSTRACTS: 1186, 3746, 3763, 3776, 3824, 6367, 6384, 6396, 6424, 6427, 6436, 6438,
CHICAGO ― Researchers from The University of Texas MD Anderson Cancer Center will present breakthrough studies in 12 minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025. Findings span various cancer types and cover topics such as innovations in immunology, experimental therapeutics, cancer prevention,...
AACR: Five MD Anderson researchers honored with 2025 Scientific Achievement Awards
Five scientists from The University of Texas MD Anderson Cancer Center will be recognized with Scientific Achievement Awards and honors at...
AACR: MD Anderson’s John Weinstein elected Fellow of the AACR Academy
CHICAGO ― John N. Weinstein, M.D., Ph.D., chair of Bioinformatics and Computational Biology and professor of Systems Biology...
NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.
Results from the Phase I trial, published today in Nature Medicine, demonstrated an overall...
